The first-line therapy in NSCLC is mainly based on the levels of PD-L1 expression in patient biopsies, and in both histological types (adenocarcinoma and squamous cell carcinoma), the first-line treatment includes chemotherapy and immunotherapy combinations. The gene discussed is CD274; the disease is non-small cell lung carcinoma.